{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:23:58Z","timestamp":1791343438514,"version":"4.3.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T00:00:00Z","timestamp":1429488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/nm.3828","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T12:45:07Z","timestamp":1429533907000},"page":"512-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":602,"title":["Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion"],"prefix":"10.1038","volume":"21","author":[{"given":"Caroline","family":"Bonner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kerr-Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Gmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvan","family":"Queniat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka","family":"Moerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Th\u00e9venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Beaucamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Delalleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy J","family":"Malaisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Deprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Abderrahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,20]]},"reference":[{"key":"BFnm3828_CR1","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn, S.E., Cooper, M.E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068\u20131083 (2014).","journal-title":"Lancet"},{"key":"BFnm3828_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1358\/dot.2013.49.5.1964714","volume":"49","author":"KM Demaris","year":"2013","unstructured":"Demaris, K.M. & White, J.R. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 49, 289\u2013301 (2013).","journal-title":"Drugs Today (Barc)"},{"key":"BFnm3828_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"SA Jabbour","year":"2008","unstructured":"Jabbour, S.A. & Goldstein, B.J. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279\u20131284 (2008).","journal-title":"Int. J. Clin. Pract."},{"key":"BFnm3828_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513\u2013519 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnm3828_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/jc.2009-0473","volume":"95","author":"S Nair","year":"2010","unstructured":"Nair, S. & Wilding, J.P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 34\u201342 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnm3828_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509\u2013514 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnm3828_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499\u2013508 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnm3828_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.physiol.68.040104.124723","volume":"68","author":"SB Biddinger","year":"2006","unstructured":"Biddinger, S.B. & Kahn, C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123\u2013158 (2006).","journal-title":"Annu. Rev. Physiol."},{"key":"BFnm3828_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF00253736","volume":"23","author":"RA DeFronzo","year":"1982","unstructured":"DeFronzo, R.A., Simonson, D. & Ferrannini, E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23, 313\u2013319 (1982).","journal-title":"Diabetologia"},{"key":"BFnm3828_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0026-0495(88)90023-6","volume":"37","author":"PJ Campbell","year":"1988","unstructured":"Campbell, P.J., Mandarino, L.J. & Gerich, J.E. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 37, 15\u201321 (1988).","journal-title":"Metabolism"},{"key":"BFnm3828_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/diacare.15.3.430","volume":"15","author":"A Consoli","year":"1992","unstructured":"Consoli, A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15, 430\u2013441 (1992).","journal-title":"Diabetes Care"},{"key":"BFnm3828_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF00400639","volume":"38","author":"S Dinneen","year":"1995","unstructured":"Dinneen, S., Alzaid, A., Turk, D. & Rizza, R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38, 337\u2013343 (1995).","journal-title":"Diabetologia"},{"key":"BFnm3828_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2337\/diab.36.3.274","volume":"36","author":"AD Baron","year":"1987","unstructured":"Baron, A.D., Schaeffer, L., Shragg, P. & Kolterman, O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36, 274\u2013283 (1987).","journal-title":"Diabetes"},{"key":"BFnm3828_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1172\/JCI106297","volume":"49","author":"RH Unger","year":"1970","unstructured":"Unger, R.H., Aguilar-Parada, E., Muller, W.A. & Eisentraut, A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49, 837\u2013848 (1970).","journal-title":"J. Clin. Invest."},{"key":"BFnm3828_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(74)92071-6","volume":"2","author":"FP Alford","year":"1974","unstructured":"Alford, F.P. et al. Glucagon control of fasting glucose in man. Lancet 2, 974\u2013977 (1974).","journal-title":"Lancet"},{"key":"BFnm3828_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00125-012-2775-y","volume":"56","author":"S Gargani","year":"2013","unstructured":"Gargani, S. et al. Adaptive changes of human islets to an obesogenic environment in the mouse. Diabetologia 56, 350\u2013358 (2013).","journal-title":"Diabetologia"},{"key":"BFnm3828_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cell.2013.04.008","volume":"153","author":"P Yi","year":"2013","unstructured":"Yi, P., Park, J.S. & Melton, D.A. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 153, 747\u2013758 (2013).","journal-title":"Cell"},{"key":"BFnm3828_CR18","doi-asserted-by":"publisher","first-page":"13209","DOI":"10.1073\/pnas.94.24.13209","volume":"94","author":"M Stoffel","year":"1997","unstructured":"Stoffel, M. & Duncan, S.A. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc. Natl. Acad. Sci. USA 94, 13209\u201313214 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3828_CR19","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.0730870100","volume":"100","author":"J Rhee","year":"2003","unstructured":"Rhee, J. et al. Regulation of hepatic fasting response by PPARgamma coactivator-1\u03b1 (PGC-1): requirement for hepatocyte nuclear factor 4\u03b1 in gluconeogenesis. Proc. Natl. Acad. Sci. USA 100, 4012\u20134017 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3828_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2337\/diabetes.53.4.1134","volume":"53","author":"LD Love-Gregory","year":"2004","unstructured":"Love-Gregory, L.D. et al. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4\u03b1 gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. Diabetes 53, 1134\u20131140 (2004).","journal-title":"Diabetes"},{"key":"BFnm3828_CR21","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.2337\/diabetes.53.11.3002","volume":"53","author":"MN Weedon","year":"2004","unstructured":"Weedon, M.N. et al. Common variants of the hepatocyte nuclear factor-4\u03b1 P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes 53, 3002\u20133006 (2004).","journal-title":"Diabetes"},{"key":"BFnm3828_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723\u20131729 (2008).","journal-title":"Diabetes"},{"key":"BFnm3828_CR23","doi-asserted-by":"publisher","first-page":"20925","DOI":"10.1073\/pnas.1212870110","volume":"109","author":"B Leibiger","year":"2012","unstructured":"Leibiger, B. et al. Glucagon regulates its own synthesis by autocrine signaling. Proc. Natl. Acad. Sci. USA 109, 20925\u201320930 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3828_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2013.11.019","volume":"103","author":"E Gylfe","year":"2014","unstructured":"Gylfe, E. & Gilon, P. Glucose regulation of glucagon secretion. Diabetes Res. Clin. Pract. 103, 1\u201310 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"BFnm3828_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cmet.2013.10.014","volume":"18","author":"Q Zhang","year":"2013","unstructured":"Zhang, Q. et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 18, 871\u2013882 (2013).","journal-title":"Cell Metab."},{"key":"BFnm3828_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"M Mueckler","year":"2013","unstructured":"Mueckler, M. & Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34, 121\u2013138 (2013).","journal-title":"Mol. Aspects Med."},{"key":"BFnm3828_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Y Fujimori","year":"2008","unstructured":"Fujimori, Y. et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327, 268\u2013276 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm3828_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","volume":"60","author":"MJ Jurczak","year":"2011","unstructured":"Jurczak, M.J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60, 890\u2013898 (2011).","journal-title":"Diabetes"},{"key":"BFnm3828_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1124\/jpet.113.203869","volume":"345","author":"N Kojima","year":"2013","unstructured":"Kojima, N., Williams, J.M., Takahashi, T., Miyata, N. & Roman, R.J. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 345, 464\u2013472 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm3828_CR30","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell, D.R. et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metab. 304, E117\u2013E130 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnm3828_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1254\/jphs.12089FP","volume":"120","author":"A Tahara","year":"2012","unstructured":"Tahara, A. et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J. Pharmacol. Sci. 120, 36\u201344 (2012).","journal-title":"J. Pharmacol. Sci."},{"key":"BFnm3828_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.112.191593","volume":"341","author":"M Suzuki","year":"2012","unstructured":"Suzuki, M. et al. Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J. Pharmacol. Exp. Ther. 341, 692\u2013701 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm3828_CR33","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 7, e30555 (2012).","journal-title":"PLoS ONE"},{"key":"BFnm3828_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","volume":"14","author":"G Luippold","year":"2012","unstructured":"Luippold, G., Klein, T., Mark, M. & Grempler, R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes. Metab. 14, 601\u2013607 (2012).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnm3828_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1124\/jpet.113.203125","volume":"345","author":"K Yamaguchi","year":"2013","unstructured":"Yamaguchi, K. et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J. Pharmacol. Exp. Ther. 345, 52\u201361 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm3828_CR36","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny, J.J. et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20, 1645\u20131652 (2012).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnm3828_CR37","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1152\/ajpendo.00545.2012","volume":"304","author":"T Nagata","year":"2013","unstructured":"Nagata, T. et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am. J. Physiol. Endocrinol. Metab. 304, E414\u2013E423 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnm3828_CR38","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","volume":"26","author":"PE Cryer","year":"2003","unstructured":"Cryer, P.E., Davis, S.N. & Shamoon, H. Hypoglycemia in diabetes. Diabetes Care 26, 1902\u20131912 (2003).","journal-title":"Diabetes Care"},{"key":"BFnm3828_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","volume":"38","author":"RA DeFronzo","year":"1989","unstructured":"DeFronzo, R.A., Ferrannini, E. & Simonson, D.C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38, 387\u2013395 (1989).","journal-title":"Metabolism"},{"key":"BFnm3828_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000338487","volume":"29","author":"C Jurysta","year":"2012","unstructured":"Jurysta, C. et al. Glucose transport by acinar cells in rat parotid glands. Cell. Physiol. Biochem. 29, 325\u2013330 (2012).","journal-title":"Cell. Physiol. Biochem."},{"key":"BFnm3828_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1523-1755.2005.00053.x","volume":"67","author":"D Magen","year":"2005","unstructured":"Magen, D., Sprecher, E., Zelikovic, I. & Skorecki, K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int. 67, 34\u201341 (2005).","journal-title":"Kidney Int."},{"key":"BFnm3828_CR42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/TP.0b013e3181d154ac","volume":"89","author":"J Kerr-Conte","year":"2010","unstructured":"Kerr-Conte, J. et al. Upgrading pretransplant human islet culture technology requires human serum combined with media renewal. Transplantation 89, 1154\u20131160 (2010).","journal-title":"Transplantation"},{"key":"BFnm3828_CR43","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1007\/s00125-011-2283-5","volume":"54","author":"C Dorrell","year":"2011","unstructured":"Dorrell, C. et al. Transcriptomes of the major human pancreatic cell types. Diabetologia 54, 2832\u20132844 (2011).","journal-title":"Diabetologia"},{"key":"BFnm3828_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/002215540104900412","volume":"49","author":"B Lukowiak","year":"2001","unstructured":"Lukowiak, B. et al. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe. J. Histochem. Cytochem. 49, 519\u2013528 (2001).","journal-title":"J. Histochem. Cytochem."},{"key":"BFnm3828_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cmet.2009.01.003","volume":"9","author":"FT Schulthess","year":"2009","unstructured":"Schulthess, F.T. et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 9, 125\u2013139 (2009).","journal-title":"Cell Metab."},{"key":"BFnm3828_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1472-6750-10-28","volume":"10","author":"B Lefebvre","year":"2010","unstructured":"Lefebvre, B. et al. Efficient gene delivery and silencing of mouse and human pancreatic islets. BMC Biotechnol. 10, 28 (2010).","journal-title":"BMC Biotechnol."},{"key":"BFnm3828_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/dmd.109.029165","volume":"38","author":"M Obermeier","year":"2010","unstructured":"Obermeier, M. et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 38, 405\u2013414 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"BFnm3828_CR48","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2337\/db12-0347","volume":"62","author":"R Cheng-Xue","year":"2013","unstructured":"Cheng-Xue, R. et al. Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K(ATP) channels from both alpha-cells and delta-cells. Diabetes 62, 1612\u20131622 (2013).","journal-title":"Diabetes"},{"key":"BFnm3828_CR49","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00125-007-0642-z","volume":"50","author":"A Abderrahmani","year":"2007","unstructured":"Abderrahmani, A. et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50, 1304\u20131314 (2007).","journal-title":"Diabetologia"},{"key":"BFnm3828_CR50","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1371\/journal.pone.0000898","volume":"2","author":"HJ de Jonge","year":"2007","unstructured":"de Jonge, H.J. et al. Evidence based selection of housekeeping genes. PLoS ONE 2, e898 (2007).","journal-title":"PLoS ONE"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3828","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:49:46Z","timestamp":1684435786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,20]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFnm3828"],"URL":"https:\/\/doi.org\/10.1038\/nm.3828","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,20]]},"assertion":[{"value":"2 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}